• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Mycoses . Prevalence, Risk Factors, Treatment and Outcome of multidrug resistance Candida auris Infections in Coronavirus Disease (COVID-19) Patien

tetano

Editor, Senior Moderator
Mycoses


. 2022 Apr 20.
doi: 10.1111/myc.13447. Online ahead of print.
Prevalence, Risk Factors, Treatment and Outcome of multidrug resistance Candida auris Infections in Coronavirus Disease (COVID-19) Patients: A Systematic Review


Kalaiselvi Vinayagamoorthy[SUP] 1 [/SUP], Kalyana Chakravarthy Pentapati[SUP] 2 [/SUP], Hariprasath Prakash[SUP] 3 [/SUP]



Affiliations

Abstract

Background: Candida auris is an emerging multidrug-resistant pathogen in intensive care settings (ICU). During the coronavirus disease 19 (COVID-19) pandemic, ICU admissions were overwhelmed, possibly contributing to the C. auris outbreak in COVID-19 patients.
Objectives: The present systematic review addresses the prevalence, underlying diseases, iatrogenic risk factors, treatment and outcome of C. auris infections in COVID-19 patients.
Methods: MEDLINE, Scopus, Embase, Web of Science and LitCovid databases were systematically searched with appropriate keywords from 1[SUP]st[/SUP] January 2020 to 31[SUP]st[/SUP] December 2021.
Results: A total of 97 cases of C. auris were identified in COVID-19 patients. The prevalence of C. auris infections in COVID-19 patients was 14%. The major underlying diseases were diabetes mellitus (42.7%), hypertension (32.9%), and obesity (14.6%), followed by the iatrogenic risk factors such as a central venous catheter (76.8%%) intensive care unit (ICU) stay (75.6%), and broad-spectrum antibiotic usage (74.3%). There were no significant differences in underlying disease and iatrogenic risk factors among C. auris non-candidemia/colonisation and C. auris candidemia cases. The mortality rate of the total cohort is 44.4%, whereas, in C. auris candidemia patients, the mortality was 64.7%.
Conclusion: This study shows that the prevalence of C. auris infections remains unchanged in the COVID-19 pandemic. Hospital-acquired risk factors may contribute to the clinical illness. Proper infection control practices and hospital surveillance may stop future hospital outbreaks during the pandemic.

Keywords: Candida auris; COVID-19; candidemia; mortality; prevalence; systematic review.
 
Back
Top Bottom